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a b s t r a c t
Background and purpose: Recently, positive data from several randomized controlled trials
(RCTs) of endovascular therapy for acute ischemic stroke (AIS) has emerged. The aim of this
retrospective study is to present our clinical experience in cerebral vessel occlusion treat-
ment using retrievable intracranial stents.
Methods: Forty-three consecutive patients with ischemic stroke (median age 75, range 22–87)
treated by stent retriever thrombectomy (SolitaireTM FR) between January 2013 and December
2015 were identiﬁed. We retrospectively assessed Thrombolysis in Cerebral Infarction (TICI)
scale (2b–3 considered as successful recanalization), clinical outcome using modiﬁed Rankin
scale (mRs) at 3 months (regarding score 0–2 as good clinical outcome), device-related
complications and symptomatic intracranial hemorrhage (sICH; parenchymal hematoma Type
1 or 2 and National Institutes of Health Stroke Scale [NIHSS] score increment ≥4 points) rate.
Results: The mean NIHSS score on admission was 16.4 (median 16). The mean time from
onset to groin puncture (time to treatment) was 290 min (median 254 min). Successful
recanalization was achieved in 30 (69.8%) cases. The mean time from onset to successful
reperfusion or procedure termination (time to reperfusion) was 394 min (median 375 min).
Good outcome was observed in 17 (39.5%) patients and mortality was 27.9% (n = 12). We
found 2 (4,7%) sICHs, one (2,3%) thromboembolic event in different vascular territory and one
(2,3%) groin hematoma.
Conclusion: Stent retriever thrombectomy for the treatment of ischemic stroke is safe, provides
high rate of recanalization and good clinical outcomes in the setting of large vessel occlusion.
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1. Introduction
The main goal of therapy in acute ischemic stroke (AIS) is
based on the ‘‘ﬂow-restoration hypothesis’’. It assumes that
reopening (recanalization) of the occluded artery and recover-
ing blood ﬂow (reperfusion) prevents salvageable brain tissue
from irreversible damage (infarction). Conﬁrmingly, recanali-
zation is strongly associated with improved functional out-
comes and reduced mortality [1]. Current standard treatment
method, aiming at restoration of cerebral blood ﬂow, is
intravenous thrombolysis (IVT) with recombinant tissue
Table 1 – Interventions among 1,342 patients with AIS
treated at our Department.
AIS (n = 1342) n (%)
IVT 287 (21.3)
Patients initially qualiﬁed for EVTa 54 (4)
Intra-arterial rt-PA only 7 (0,5)
Mechanical thrombectomy only 38 (2.8)
Intra-arterial rt-PA + mechanical thrombectomy 5 (0.4)
a Explanation in text.
Abbreviations: AIS, acute ischemic stroke; IVT, intravenous throm-
bolysis; rt-PA, recombinant tissue plasminogen activator.
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signiﬁcant beneﬁcial effect [2]. However, intravenous rt-PA use
is limited by narrow therapeutic time window (<4.5 h) and
several important contraindications (i.e., coagulopathy, recent
major surgery, active bleeding). Furthermore, acute recanali-
zation rates in patients with large vessel occlusion (LVO) of the
main cerebral artery treated by IVT are as low as 20% [3,4]. Only
10–15% of internal carotid artery (ICA) and 30–50% of proximal
medial cerebral artery (MCA) occlusions recanalize, which
corresponds with poor clinical outcomes [5–7]. What's impor-
tant LVO is responsible for approximately one-third to one-
half of AIS [8]. Ultimately, there is a signiﬁcant proportion of
patients that are either ineligible or relatively resistant to
systemic thrombolysis.
Constraints in IVT use have led to investigation of other
revascularization methods. Over the past years endovascular
treatment (EVT), comprising of intra-arterial rt-PA delivery
and mechanical clot-retraction, continued to rapidly evolve. In
early randomized controlled trials (RCTs) it provided higher
recanalization rates, although failed to show superiority over
standard medical treatment [5,9,10]. Several limitations of
those trials have been widely described, such as no pre-
procedural vascular imaging selection, older generation
devices used or signiﬁcant time to treatment delay [11]. More
recently, various RCTs proved remarkable clinical outcomes
improvement among patients treated with EVT comparing to
standard treatment. Newer devices, i.e., stent retrievers,
predominantly used among those trials, presented even
greater recanalization rates and minimized procedure dura-
tion [12–16]. Gathering of data from conducted RCTs has led to
development of clinical guidelines with highest-level of
evidence recommendations in Europe [17] and United States
[18].
The purpose of our study is to present our clinical
experience in endovascular treatment of acute ischemic
stroke using stent retriever devices. The use of this treatment
method is limited in Poland owing to shortage of endovascular
treatment facilities and lack of state funding. Local literature
on this topic is insufﬁcient as well [19]. Our effort is to ﬁll this
information gap.
2. Materials and methods
2.1. Patients
Between January 2013 and December 2015 1,342 patients were
diagnosed with AIS at our Stroke Unit (Department ofNeurology, Clinical Voividship Hospital No. 2, Rzeszów,
Poland). Two hundred eighty-two (21.3%) were treated with
IVT. Fifty-four (4%) had an LVO proved by CT angiography and
was qualiﬁed for EVT (Table 1). Among those, there were two
cases of recanalization after IVT shown by pre-procedural
digital subtraction angiography (DSA) and in the other two we
failed to catheterize the aimed vessel due to anatomical
difﬁculties. Seven patients had intra-arterial rt-PA adminis-
tered as the only method of endovascular treatment. There-
fore, in this study we retrospectively reviewed the records of
forty-three consecutive patients (median age 75, range 22–87)
treated with stent retriever thrombectomy. All procedures was
conducted with the Solitaire FR device. In 38 (88%) cases it was
used as the only technique and the other 5 (12%) had
additional intra-arterial rt-PA applied. Only one (2.3%) patient
was transported from another hospital to perform endovas-
cular procedure at our Department.
2.2. Procedure
All subjects had initial non-contrast CT imaging and clinical
evaluation by neurologist as part of our standard algorithm
and, if eligible, had IVT administered (n = 28; 65%). Noninva-
sive vascular imaging by CT angiography was performed in
each case. When LVO (occlusion of internal carotid artery [ICA]
terminus, ﬁrst segment of middle cerebral artery [MCA-M1],
second segment of middle cerebral artery [MCA-M2], basilar
artery [BA], posterior cerebral artery [PCA], vertebral artery
[VA]) was conﬁrmed, further inclusion and exclusion criteria
were assessed (Tables 2 and 3). Exceptions from the predeﬁned
criteria were allowed at the discretion of endovascular
treatment team (experienced vascular neurologist and neuro-
radiologist).
Two (4.7%) patients had EVT conducted despite mild
neurological deﬁcit measured by National Institutes of Health
Stroke Scale (NIHSS score <6) and one (2.3%) was functionally
dependent before stroke onset (modiﬁed Rankin scale [mRS]
score 3) due to prior lower limb amputation. In a single case
(2.3%) MCA-M3 occlusion was the aim of treatment. Once
(2.3%) EVT was proceeded after performing emergency
cesarean section in a woman at 35 weeks gestation. In each
particular subject risk in relation to potential beneﬁt were
carefully evaluated.
Twenty-seven (62.8%) procedures were performed under
general anesthesia. In patients with anterior circulation
occlusion we used 8F sheath introducer (Super Arrow-Flex;
Teleﬂex, Limerick, Pennsylvania) and 8F balloon catheter
Table 2 – Inclusion criteria for the mechanical throm-
bectomy.
Inclusion criteria Patients treated without
meeting criterion n (%)
The clinical diagnosis of acute
ischemic stroke (exclusion of
cerebral hemorrhage on CT scan)
Age ≥18
NIHSS ≥6 2 (4.7%)
Capability to start treatment before
8 h (or 15 h for posterior
circulation occlusion)
from onset of symptoms
Angio-CT conﬁrmed large vessel
occlusion (terminal ICA, MCA-M1,
MCA-M2, VA, BA, PCA)
1 (2.3%)
No improvement or exclusion
from systemic thrombolysis
mRS ≤2 before treatment 1 (2.3%)
Consent to treatment
Table 3 – Exclusion criteria for the mechanical throm-
bectomy.
Exclusion criteria
Glucose <50 mg% or >400 mg%
Hemorrhagic diathesis or coagulation factors deﬁcit
International Normalized Ratio (INR) >3
The use of heparin within 48 h before treatment and Activated
Partial Thromboplastin Time (APTT) prolonged more than twice
the upper laboratory limit
Thrombocytopenia < 30,000/mm3
Radiological evidence of signiﬁcant mass effect with the midline
shift or ischemic injury involving more than one third of the
MCA territory
Concomitant myocardial infarction or severe infection (sepsis,
infectious endocarditis)
A history of stroke within previous 30 days
Systolic >185 mmHg and diastolic blood pressure >110 mmHg
despite intensive treatment
Pregnancya
History of radiographic agents allergic reaction
Predicted life expectancy ≤3 months for the reason other than
current stroke
a One (2.3%) patient was treated despite being pregnant at the
stroke onset.
Table 4 – Localization of vessel occlusions.
Location (n = 44) n (%)







Abbreviations: ICA, internal carotid artery; M1, ﬁrst segment of
middle cerebral artery; M2, second segment of middle cerebral
artery; M3, third segment of middle cerebral artery; BA, basilar
artery; PCA, posterior cerebral artery
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to gain ICA access. Microcatheter (Rebar 18 or 027, Covidien,
Irvine, California, USA) was then advanced for the Solitaire 2
FR device (size 4 mm  30 mm, 4 mm  20 mm or
4 mm  15 mm) over a hydrophilic guidewire (X-pedion 10
or 14, Covidien, Irvine, California, USA) to cross the thrombus.
After contrast injection, clot length and vessel diameter were
assessed to introduce adequately sized Solitaire stent. The
device was unsheathed partially within, partially distal to the
thrombus and held in position for 5 min. Angiographic run was
then performed to determine revascularization status. Before
system removal, balloon catheter was inﬂated at the level of
upper ICA. Suction was applied through the guide catheter
during thrombus evacuation. The procedure was repeated
until successful recanalization (TICI 2b, 3) or ﬁfth device pass(predeﬁned upper limit). When residual distal vessel occlusion
was conﬁrmed, further endovascular treatment was applied at
the discretion of endovascular treatment team. In case of
posterior circulation vessel occlusion ordinary guide catheter
instead of balloon catheter was used.
We employed intra-arterial thrombolysis in case of
technical difﬁculties due to vessel tortuosity, distal vessel
occlusion (M2 or M3 portion of MCA) or mechanical clot
removal failure. A follow-up CT scan between 24 and 36 h after
procedure was performed in all cases.
2.3. Imaging and clinical assessment
Assessment of recanalization was based on Thrombolysis in
Cerebral Infarction (TICI) score, with grades 2b and 3 regarded
as being successful. We calculated time to treatment as the
time between onset of symptoms to groin puncture. The time
to reperfusion was deﬁned as the time to successful reperfu-
sion or the end of the procedure in cases for which it was not
achieved.
Patients were evaluated applying NIHSS on admission, 24 h
and 7 days after treatment. Subjects who died had no NIHSS
score assigned and were not included in analyses of such
scores. Functional outcomes at 3 months were determined
during outpatient follow-up or by telephone interview with the
patient, proxy or health care provider. The mRS score was used
(≤2 considered as good clinical outcome). We investigated
patients records in search for procedural complications, such
as: vessel dissection or perforation, remote vascular territory
embolization, groin hematoma and symptomatic intracranial
hemorrhage (sICH; parenchymal hematoma Type 1 or paren-
chymal hematoma Type 2 with NIHSS score increment ≥4
points).
3. Results
Forty-three patients (median age 75, range 22–87) were
diagnosed with AIS proved to be caused by intracranial LVO
and were treated with stent retriever thrombectomy. Among
those, 44 procedures were performed (in one case there was
simultaneous anterior cerebral artery [ACA] and MCA occlu-
sion). Twenty-eight (65.1%) subjects had prior IVT adminis-
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Fig. 1 – The mean NIHSS score at admission, 24 h and 7 days after treatment.
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Table 4. Thirty-seven patients had the pattern of anterior
and six of posterior circulation obstruction. Early ischemic
changes were found on the pretreatment CT scan in 16 (37.2%)
cases.
The mean time to treatment was 290 min (range 120–885,
median 254 min) and mean time to reperfusion equaled
394 min (range 170–1045, median 375 min). Successful recana-
lization was achieved in 30 (69.8%) cases. Eleven (25.6%)
attempts failed to obtain recanalization (TICI 0). The mean
duration of procedure was 103 min (range 35–215, median
95 min).
The mean values of NIHSS score on admission, at 24 h and 7
days of treatment are shown in the Fig. 1. One patient died
before the 24-h and other seven before the seventh day
evaluation. The mean NIHSS score assessed both at 24 h and
seven days after treatment was higher in the posterior, than
anterior circulation LVO subgroup (22.2 vs 15.7 and 17.2 vs 10.9,
in the order given). On admission it was 16 and 16.4,2 7 8 3 4 
0% 10 % 20 % 30 % 40 % 50 %
mRS at 3 mo n
0 1 2 3
Fig. 2 – Distribution of mRS scoresrespectively. The overall mortality at the discharge was
18.6% (n = 8).
At 3 months good clinical outcome (mRS ≤2) was achieved
in 17 (39.5%) cases and mortality rate was 27.9% (n = 12). When
comparing posterior to anterior circulation occlusion cohort,
functional independence was achieved in 50% vs 37.8% and
mortality in 33.3% vs 27% of patients, respectively. Distribution
of mRS scores is shown in the Fig. 2.
We found 2 (4.7%) cases of sICH, one (2.3%) thromboembolic
event in the other vascular territory (ACA embolization during
MCA occlusion treatment) and one (2.3%) groin hematoma that
did not require surgical intervention. The overall periproce-
dural complication rate was 9.3% (n = 4).
4. Discussion
Mechanical clot retrieval has lately become highest level of
evidence-based method of AIS treatment in carefully selected7 12
60 % 70 % 80 % 90 % 100%
ths  (n=43)
 4 5 6
 at 3 months after treatment.
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however, conducted before the European EVT guidelines
emergence and the patient qualiﬁcation process differed
substantially from the currently recommended. Nonetheless,
satisfying recanalization rates and clinical outcomes were
achieved.
Five recently published RCTs (MR CLEAN [12], ESCAPE [13],
EXTEND-1A [14], SWIFT PRIME [15], REVASCAT [16]) have
proved beneﬁts of endovascular AIS treatment in the setting of
anterior circulation LVO. Similarly to our case series second-
generation mechanical thrombectomy devices (stent retrie-
vers) were predominantly used among those trials. In contrast
to previous reports (IMS III [5] and MR RESCUE[9]), where
almost exclusively intra-arterial rt-PA and ﬁrst-generation
devices had been employed, successful recanalization rates as
high as 59% to 88% (vs 25% to 41%) were obtained [17]. It
corresponds well with our results of 69.8% patients with TICI
scale 2b/3 scores. Our cohort was, however, more heteroge-
neous including 6 (14%) posterior, apart from 37 (86%) anterior
circulation occlusion cases. Those patients were a priori
excluded from previously mentioned trials. Nonetheless,
some evidence from single-center studies concerning posteri-
or circulation LVO exists. It has shown recanalization rates
over 75% following basilar artery thrombectomy using newer
generation devices [20,21]. In this series, successful recanali-
zation was achieved in 83% (n = 5) of patients with either BA or
PCA occlusion. These data suggests that mechanical stent
retriever thrombectomy may be very effective in regaining
vessel patency in the settings of posterior circulation occlu-
sion.
Good clinical outcomes (mRS ≤2) at 3 months was observed
in 17 of 43 (39.5%) cases. These results are satisfying comparing
to 33% in the endovascular arm of MR CLEAN study. However,
when referring to the meta-analysis by Campbell et al. that
pooled data from 4 recent RCTs predominantly using Solitaire
device (ESCAPE, EXTEND-1A, SWIFT PRIME, REVASCAT),
higher proportion (54%) of patients in the treatment arm
was observed to be functionally independent (mRS 0–2) [22].
There are several features of our patient and procedural
characteristics that might contribute to the difference in
clinical results. Firstly, the prestroke function eligibility
criterion was less strict (0–2 mRS) than in the ESCAPE, SWIFT
PRIME and REVASCAT studies (0–1 mRS or Barthel score of
>90–100), whereas EXTEND-1A, obtaining the highest rate
(71%) of good clinical outcomes, allowed only 4.5-h treatment
window. Besides, lower portion of our cohort had IVT
conducted (65% vs 80.5%). We used no speciﬁc pretreatment
patient selection based on CT perfusion or ASPECTS score
(Alberta Score Program Early CT Score), which could led to
treatment of subjects with initial worse prognosis. Moreover,
there was longer median time from stroke onset to arterial
access (254 vs 225 min). The higher median time to recanali-
zation (375 vs 274 min), caused mainly by procedure length
(median 95 vs 38) is also worth noting. The reasons for
procedure elongation were mainly residual distal occlusion
treatment and limited anesthesiologist availability.
The beneﬁt of EVT shown in MR CLEAN study was
demonstrated to be time dependent in subsequent report
[23]. There was no statistically signiﬁcant treatment effect
when time to reperfusion exceeded 6 h and 19 min. Based onthis and other [7,24] analyses, recommendation of treating as
early as possible, until it can be initiated within 6 h of
symptom onset, was proposed in current guidelines [17,18]. In
this case series we managed to obtain time to reperfusion
under 6 h in only 49% (n = 21) of patients. This subgroup shown
trend to better outcomes with higher rates of functional
independence (0–2 mRS) after 3 months (47,6% vs 31,8%,
p = 0.36, Fisher's exact test) and lower mortality rates (13.6% vs
40.9%, p = 0.09) comparing to longer time to reperfusion cohort,
although both failed to reach statistical signiﬁcance. If there is
a group of patients that could beneﬁt from EVT conducted after
6 h of stroke onset still needs investigation [17].
In our EVT qualiﬁcation protocol waiting period after IVT
initiation was advocated to verify absence of early clinical
improvement. Since reperfusion delay was conﬁrmed to
worsen clinical outcomes, new recommendation to abandon
observation time and immediately proceed with mechanical
thrombectomy appeared [17,18]. This treatment lag could
inﬂuence our study results.
In this series mortality during 3-months observation
equaled 27.9% (n = 12), and was higher than detected in the
intervention arm of MR CLEAN study (21%). However, being
older (median age 75 vs 68, interquartile range 61–80 vs 55–76),
our cohort could have had initial poorer prognosis [25]. There
was signiﬁcantly higher mortality among subjects evaluated
0–2a comparing to 2b-3 at the post-treatment TICI score
assessment (53.9% vs 16.7%, p = 0.02. Fisher's exact test).
Analyzing the death causes, two (16.7%) patients died of
symptomatic cerebral hemorrhage, one (8.3%) due to subse-
quently diagnosed malignancy, one (8.3%) of pulmonary
embolism and three (25%) of pneumonia. Three (25%) deaths
were a result of malignant cerebral infarction and there was no
stated cause in 4 (33.3%) cases.
Overall complication rate in our series was 9.3% (n = 4). We
detected symptomatic intracranial hemorrhage in 4.7% (n = 2)
of cases, which is consistent with 5.7% shown in the
mechanical EVT meta-analysis by Badhiwala and colleagues
[26]. Lower sICH rate (2.5%) was identiﬁed by Campbell et al. in
Solitaire thrombetomy meta-analysis [22]. We also observed
one (2.3%) periprocedural thromboembolic event in the
remote vascular territory. The ACA was occluded with the
fragment of thrombotic material lost during device with-
drawal. There was, however, no functional impairment at 3
months noted in this patient (mRS score 0). In one (2.3%)
subject groin hematoma that was successfully treated
conservatively arose.
Our retrospective study provides single-center experience
of mechanical thrombectomy with the stent retriever device
(Solitaire FR). Results of this case series are consistent with the
evidence from recently published RCTs, conﬁrming the safety
and efﬁcacy of this method in AIS treatment [12–16]. We,
nonetheless, present more heterogeneous cohort including
patients with posterior circulation and distal portions of MCA
(M2, M3) occlusions, with broader time to treatment window,
and unselected by means of advanced imaging techniques (CT
perfusion) or ASPECTS score. Clearly, some of our qualiﬁcation
criteria require modiﬁcation (treatment window) and other
(BA, PCA, MCA M2, MCA M3 occlusions, CT early ischemic
changes, minor neurological deﬁcit) need to be validated by
further RCTs.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 1 2 – 1 8 17This relatively small case series does not permit to draw
adequate conclusions, but rather conﬁrms data from large
RCTs in the clinical settings. It has the limitations attributed to
case series methodology.
5. Conclusions
Stent retriever thrombectomy for the treatment of acute
large vessel occlusion provides high rate of recanalization
and good clinical outcomes with acceptable complication
rates. It's efﬁcacy decreases with the treatment delay. Our
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